Cancer Chemotherapy Reviews
Thursday, March 28, 2024 
ISSN: 2462-4136
 
Subscribers area
Home Editorial Board Journal Contents Subscriptions Contact Us Authors Instructions
     
   
<<< back |
REVIEW ARTICLE

Exploratory Analysis of Latin American Patients in Two Randomized, Phase III Studies of Ramucirumab Alone or with Paclitaxel for Advanced Gastric Cancer

July-September 2015, Volume 02, Number 3
Fernando Meton-Vieira, Lucas Vieira dos Santos, Gustavo Girotto, Guillermo Mendez, Rebecca Cheng, Yanzhi Hsu and Mauro Orlando
National Cancer Institute INCA, Rio de Janeiro, Brazil
 

Treatment with ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody vascular endothelial growth factor-receptor-2 antagonist, in two global phase III randomized trials (REGARD and RAINBOW), demonstrated significant improvements in overall and progression-free survival in patients with previously treated advanced gastric cancer. This analysis aims to identify characteristics of Latin American cohorts from REGARD and RAINBOW. In the REGARD study, patients whose disease had progressed after fluoropyrimidine and/or platinum-containing chemotherapy received ramucirumab (8 mg/kg intravenously every two weeks) or placebo plus best supportive care. In the RAINBOW study, patients received either ramucirumab (8 mg/kg) or placebo on days 1 and 15 plus paclitaxel 80 mg/m2 on days 1, 8, and 15 (28-day cycle). Post hoc analyses of baseline patient characteristics, efficacy, and adverse events in Latin American cohorts were performed. Latin American patients comprised 16.1% (57/355) and 6.6% (44/665) of REGARD and RAINBOW intent-to-treat populations, respectively. Baseline imbalances were observed between treatment arms within the Latin American subpopulations in both trials. The survival trends in the Latin American patients appear consistent with the outcomes in the intent-to-treat population with a manageable safety profile. Inferences may be limited due to small sample size; however, according to this retrospective analysis, ramucirumab seems to be an appropriate option for Latin American patients with previously treated advanced gastric cancer.

 
 
Key words:
Gastroesophageal junction. Adenocarcinoma. Latin America. Paclitaxel. Ramucirumab. Vascular endothelial growth factor receptor-2.
 
[See pdf]
 
 
     
Temístocles, 315 – Colonia Polanco
Delegación Miguel Hidalgo
11560 Ciudad de México
© Permanyer | Made & Powered by PERMANYER | Privacy Policy - Legal notice